Margarita Lamothe, MD
Infectious Disease · Memphis, TNNPI 1306887187
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 677 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,259 and has fallen 51.4% since, to $1,097 in 2025.
Across 677 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$2K
- AbbVie$1K
- Merck$1K
- Insmed, Inc.$1K
- La Jolla Pharmaceutical Company$816
- plus $3K from 20 others
What the payments were for
- Food & beverage$11,35898%
- Education$1902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 140 | $2,214 |
| Viiv Healthcare Company | 115 | $1,687 |
| AbbVie(2 entities) | 97 | $1,341 |
| Merck | 75 | $1,249 |
| Insmed, Inc. | 45 | $1,014 |
| La Jolla Pharmaceutical Company | 46 | $816 |
| Cumberland Pharmaceuticals, Inc. | 10 | $560 |
| Pfizer | 25 | $434 |
| Theratechnologies Inc. | 22 | $371 |
| Johnson & Johnson | 24 | $335 |
| Tetraphase Pharmaceuticals, Inc. | 20 | $330 |
| Melinta Therapeutics, LLC | 16 | $237 |
| Astellas Pharma US Inc | 7 | $220 |
| Biotissue Holdings Inc. | 3 | $147 |
| Shionogi Inc | 6 | $115 |
| Ferring Pharmaceuticals Inc. | 5 | $106 |
| Mayne Pharma Commercial LLC | 5 | $74 |
| Paratek Pharmaceuticals, Inc. | 4 | $66 |
| AstraZeneca | 3 | $54 |
| EMD Serono, Inc. | 3 | $54 |
| Triad Life Sciences Inc. | 1 | $37 |
| Convatec Inc. | 1 | $25 |
| Dynavax Technologies Corporation | 1 | $20 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Medela LLC | 1 | $13 |
| Mylan Institutional Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,548 in reported general payments places this provider in the 85th percentile of 156 infectious disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 250 | $1,046,119 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 176 | $704,813 |
| TivicayDolutegravir Sodium | 144 | $379,421 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 89 | $345,826 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 65 | $241,407 |
| DescovyEmtricitabine/Tenofov Alafenam | 97 | $221,355 |
| JulucaDolutegravir/Rilpivirine | 51 | $183,483 |
| IsentressRaltegravir Potassium | 66 | $143,959 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 21 | $113,034 |
| PrezcobixDarunavir/Cobicistat | 40 | $101,804 |
| Darunavir | 67 | $55,541 |
| CompleraEmtricita/Rilpivirine/Tenof Df | 14 | $49,710 |
| CabenuvaCabotegravir/Rilpivirine | 11 | $49,211 |
| Etravirine | 34 | $29,595 |
| Vancomycin Hcl | 108 | $22,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadGenvoya, Biktarvy, Descovy | $2,214 | $1,972,287523 claims |
| Viiv Healthcare CompanyTivicay, Triumeq, Juluca, Cabenuva | $1,687 | $957,941295 claims |
| Johnson & JohnsonPrezcobix, Complera | $335 | $151,51454 claims |
| MerckIsentress | $1,249 | $143,95966 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 156 infectious disease providers in Tennessee.
Other infectious disease in Memphis
- Michael GelfandMemphis$486K
- Kerry ClevelandMemphis$426K
- Stephen ThrelkeldMemphis$27K
- Imad OmerMemphis$22K
- Daniel MurrellMemphis$12K
- James DaleMemphis$8K
- Michael ThrelkeldMemphis$5K
- Kristie NowakMemphis$2K
- Shirin MazumderMemphis$2K
- Chiemeziem NwanyanwuMemphis$899
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.